Health Policy Analysis: 2026 Reforms and Their Impact on Women’s Care

The 2026 Australian women’s health reforms, backed by a $792 million package honoring Peta Murphy MP’s legacy, have already saved 340,000 women $38.3 million on menopausal hormone therapy in their first year—but critical gaps in gender mainstreaming and intersectional equity remain unaddressed. This health policy analysis evaluates the early outcomes of these reforms, including Medicare rebates for menopause care, expanded pharmacy prescribing for UTIs, and subsidized contraceptives. By examining cost savings, implementation challenges, and persistent inequities, we identify advocacy priorities for 2027 and beyond.

The Australian Government Department of Health and Aged Care announced these measures as part of a broader strategy to improve women’s health outcomes. However, a critical health policy analysis reveals that despite significant financial investments, systemic barriers continue to marginalize First Nations women, rural residents, and those with chronic conditions.

2026 Women’s Health Reforms: Critical Analysis of Early Outcomes and Cost Savings

A comprehensive health policy analysis of the 2026 women’s health reforms shows immediate financial benefits for hundreds of thousands of Australian women. The $792 million Women’s Health Package, announced in 2025, has delivered measurable cost savings through Medicare rebates, PBS subsidies, and expanded access services, complementing the comprehensive women’s health resources available to Australians. This health policy analysis evaluates the early outcomes of these health policy reforms for gender-specific care, including Medicare rebates, PBS subsidies, and expanded access services.

Menopause Care Reforms: 340,000 Women Saved $38.3M in First Year

• 340,000 women saved $38.3 million on menopausal hormone therapy (health.gov.au, Jan 3, 2026)
• 71,000+ Medicare rebates for menopause assessments processed by February 2026 (health.gov.au)
• 1.25 million scripts subsidized under the new rebates (health.gov.au)
• $792 million total Women’s Health Package funding (research notes)

The $38.3 million in savings represents approximately 4.8% of the total $792 million package, indicating substantial early uptake within the first year. With 71,000 assessments completed, this suggests a reach of about 3.5% of Australia’s estimated 2 million menopausal women. While the numbers are promising, they also highlight the need for increased awareness and accessibility to ensure the reforms benefit all women experiencing menopause, particularly those in rural and underserved communities.

PBS Savings: 328,000 Women Benefited from $27M in Subsidized Treatments

• 328,000 women saved $27 million on 660,000 scripts (openaustralia.org.au, Mar 2, 2026)
• PBS maximum co-payment reduced from $31.60 to $25 (research notes)
• Total savings of $73 million across contraceptives, menopause, and fertility treatments (pre-collected)
• Average savings: $82 per woman, $41 per script (calculated)

The reduction of the PBS co-payment from $31.60 to $25 significantly improves affordability for low-income women, effectively lowering the barrier to essential medications. The average savings of $82 per woman may seem modest, but for women managing multiple prescriptions, the cumulative impact is substantial. The broader $73 million savings across three categories demonstrates the package’s wide-reaching effect on women’s healthcare affordability.

Cancer Drug Listings: New PBS Coverage for Olaparib, Verzenio, and Keytruda

The expansion of the Pharmaceutical Benefits Scheme to include olaparib for ovarian cancer, Verzenio for breast cancer, and Keytruda for various cancers marks a significant advancement in women’s cancer care, particularly in breast cancer treatment advances. These targeted therapies have been shown to improve survival rates and quality of life for patients. By subsidizing these drugs, the reforms reduce out-of-pocket costs that previously limited access for many women.

However, eligibility criteria based on cancer stage, genetic markers, and prior treatments may create access barriers, particularly for patients in regional areas where specialist approval processes are more complex. Ongoing monitoring will be essential to ensure these listings translate into equitable outcomes.

Expanded Access: Pharmacy Prescribing for UTIs and Free Screenings

Expanding pharmacy prescribing for uncomplicated urinary tract infections allows women to obtain necessary antibiotics without a doctor’s appointment, a crucial improvement for rural communities facing doctor shortages. The provision of free breast and cervical screenings, including 3D tomosynthesis for mammograms from March 2026, enhances early detection capabilities and aligns with updated breast cancer screening guidelines. BreastScreen targets women aged 50-74, aligning with evidence-based screening guidelines.

Limitations exist: pharmacy prescribing likely covers only simple UTIs, not complicated cases requiring specialist care, and screening eligibility remains age-restricted, potentially missing younger high-risk women. These measures represent positive steps but require refinement to address all access barriers.

Implementation Gaps: Where 2026 Reforms Fall Short for Marginalized Women

Despite the promising financial outcomes, a rigorous health policy analysis reveals that the 2026 reforms fail to address systemic inequities that perpetuate poor health outcomes for marginalized women. Gender mainstreaming—the integration of gender equality into all policy stages—has not been achieved in Australia, undermining the potential for these reforms to produce equitable results. This section examines the critical gaps that leave First Nations women, rural residents, and those with chronic conditions behind, underscoring the need for integrated women’s rights and health equity advocacy.

Systemic Gender Bias: Australia’s Failure to Mainstream Gender in Health Policy

Gender mainstreaming requires that all policies consider the differential impacts on women and men from the outset. Research published in ScienceDirect in 2025 confirms that despite Australia’s OECD leadership in women’s health policy, gender mainstreaming has not been fully implemented. This systemic bias means that even well-intentioned reforms like the $792 million package may inadvertently benefit women unevenly.

For example, without mandatory sex-disaggregated data, it’s impossible to track whether subsidies reach women of all socioeconomic backgrounds equally. The establishment of the National Women’s Health Advisory Council is a positive step, but without enforcement powers, its recommendations may be ignored, perpetuating the status quo.

Intersectional Inequities: First Nations Women and Rural Access Remain Under-Served

• Unpaid care burden falls disproportionately on women, limiting workforce participation and ability to afford healthcare (Status of Women Report Card 2026, genderequality.gov.au, Mar 2026)
• Intimate partner violence affects 1 in 3 women, with inadequate integration into health system responses (Status of Women Report Card 2026)
• Gender pay gap means women have less disposable income for out-of-pocket health costs (genderequality.gov.au, Mar 2026)
• First Nations women face significant health disparities and historical distrust in health institutions (PM&C Corporate Plan 2025-26)
• Rural residents experience severe doctor shortages, with 20% of women traveling over 100km for specialist care (AI Overview)
• Women with disabilities encounter physical and informational accessibility barriers (wwda.org.au)

These intersectional gaps create compounded disadvantages. First Nations women, for instance, experience higher rates of chronic disease yet are less likely to access preventive care due to cultural insensitivity and geographic isolation. Rural women face long travel distances for specialized services like endometriosis clinics.

Women with disabilities often find health facilities inaccessible and lack trained providers. Addressing these inequities requires culturally safe, trauma-informed care that acknowledges historical injustices and actively involves marginalized communities in policy design.

AMA Critique: Pharmacy Prescribing Trials Lack Quality in Women’s Healthcare

The Australian Medical Association’s March 2026 statement criticized the pharmacy prescribing trials for lacking quality in women’s healthcare. The AMA highlighted insufficient training for pharmacists in women’s health issues, inadequate patient assessment protocols, and the absence of gender-specific considerations. For example, pharmacists may not have the expertise to differentiate between uncomplicated UTIs and more serious conditions like pelvic inflammatory disease, which requires different treatment.

This raises risks of missed diagnoses and inappropriate antibiotic use, potentially contributing to antimicrobial resistance. While expanding access is a worthy goal, the government must ensure that quality and safety are not compromised, particularly for women with complex health needs.

Data Deficits: The Critical Lack of Gender-Specific Health Metrics

Effective health policy analysis depends on robust data to measure disparities and target interventions. Currently, Australia suffers from a critical lack of gender-specific health metrics. Data on women-exclusive conditions like endometriosis, menopause, and autoimmune diseases is often incomplete or non-existent.

The National Women’s Health Advisory Council, established to guide policy, must mandate sex-disaggregated data collection across all Medicare, PBS, and hospital reporting. Without this, we cannot assess whether reforms are reducing inequities or merely shifting burdens. The Australian Women’s Health Hub’s 2025 report calls for gender-responsive knowledge mobilization, emphasizing that data is the foundation for accountability and improvement.

What’s Next? Advocacy Priorities for 2027 and Beyond

Looking ahead, health policy analysis must shift from evaluating past reforms to shaping future advocacy.

The 2026 reforms, while beneficial, leave critical areas unaddressed. This section outlines priority actions for 2027, focusing on chronic pain, economic equity, mental health integration, and robust policy monitoring to ensure that women’s health becomes truly equitable, building on existing cancer awareness initiatives to address persistent gaps.

Chronic Pain and Disability: The Unaddressed Burden of Endometriosis and Beyond

• Endometriosis: 33 clinics operational but coverage limited to major cities, leaving rural women without access (research notes)
• Fibromyalgia: Lack of Medicare item numbers for multidisciplinary pain management (wwda.org.au)
• Vulvodynia: Minimal research funding and clinical training (abc.net.au)
• Chronic fatigue syndrome: Not recognized as a disability under Medicare, hindering support (wwda.org.au)
• Pelvic floor dysfunction: Often excluded from public hospital services, requiring expensive private care (AI Overview)

The establishment of 33 endometriosis clinics is a welcome step, but these clinics are concentrated in urban centers, creating geographic barriers. Moreover, endometriosis care often requires multidisciplinary teams including gynecologists, pain specialists, and mental health professionals—services that are not fully covered by Medicare. Women with other chronic pain conditions like fibromyalgia and vulvodynia face even greater neglect, with few dedicated services or research funding.

Advocacy must demand more clinics in regional areas, new Medicare item numbers for comprehensive pain management, and increased research funding for understudied conditions. These efforts should be coupled with Medicare policy changes for women’s healthcare to ensure sustainable funding models.

Economic Equity: Linking Health Access to Unpaid Care and Pay Gap Reforms

Women’s health outcomes are inextricably linked to economic factors. Unpaid care work—predominantly performed by women—reduces workforce participation, leading to lower incomes and greater financial stress, which in turn worsens health access. The gender pay gap means women have less disposable income to cover out-of-pocket health costs, even with PBS subsidies.

The Status of Women Report Card 2026 underscores these persistent inequities. An integrated policy approach is needed: combine health funding with economic reforms such as expanded paid parental leave, affordable childcare, and pay transparency measures. According to the World Economic Forum (March 2026), every $1 invested in women’s health could generate $3 in economic growth, making this not just a moral imperative but a smart economic strategy.

Mental Health Integration: Closing the Gap in Trauma-Informed Care

Women’s mental health needs are often intertwined with trauma, particularly from intimate partner violence, which affects 1 in 3 women. The 2025-26 Budget increased funding for digital mental health platforms, but these cannot replace face-to-face, trauma-informed services that many survivors require. Current women’s health consultations rarely include mandatory mental health screening for depression, anxiety, or PTSD, missing opportunities for early intervention.

We recommend integrating standardized mental health assessments into all women’s health appointments, with clinicians trained in trauma-informed care and clear referral pathways to specialized support. This would ensure that the psychological dimensions of physical health conditions are not overlooked.

Policy Monitoring: Building Robust Evaluation Frameworks

Current Monitoring Mechanisms	Recommended Enhancements
Parliamentary reports (ad hoc)	Mandatory sex-disaggregated data collection across all health services
Basic usage metrics (e.g., number of scripts)	Intersectional health outcomes (e.g., access rates by ethnicity, location, disability)
Limited patient feedback	Patient-reported experience measures (PREMs) integrated into all women’s health services
No independent review	Annual independent evaluation by the National Women’s Health Advisory Council

Sustained monitoring is essential for accountability and course correction. Relying on occasional parliamentary reports leaves gaps in real-time data. Without sex-disaggregated metrics, we cannot detect disparities.

Without patient-reported experiences, we miss qualitative insights into care quality. An annual independent review would provide objective assessment of whether reforms are meeting their equity goals. The National Women’s Health Strategy 2020-2030 already calls for a robust monitoring and evaluation framework; the time to implement it is now.

Most surprising finding: Despite a $792 million investment, gender mainstreaming has not occurred in Australian health policy, meaning these reforms may still produce unequal outcomes for women—a systemic flaw that undermines the entire agenda. The lack of sex-disaggregated data prevents us from even measuring these disparities.

Action step: Advocate for the National Women’s Health Advisory Council to mandate comprehensive sex-disaggregated data collection across all Medicare, PBS, and hospital reporting by 2027, with public dashboards showing intersectional outcomes to ensure transparency and accountability. This single change would transform how we evaluate and improve women’s health policy in Australia.